Laboratory Diagnosis of Clostridium difficile Infection in Korea: The First National Survey
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
In May 2015, we conducted a voluntary online survey on laboratory diagnostic assays for Clostridium difficile infection (CDI) across clinical microbiology laboratories in Korea. Responses were obtained from 66 laboratories, including 61 hospitals and five commercial laboratories. Among them, nine laboratories reported having not conducted CDI assays. The toxin AB enzyme immunoassay (toxin AB EIA), nucleic acid amplification test (NAAT), and C. difficile culture, alone or in combination with other assays, were used in 51 (89.5%), 37 (64.9%), and 37 (64.9%) of the remaining 57 laboratories, respectively, and 23 (40.4%) of the laboratories performed all three assays. Only one laboratory used the glutamate dehydrogenase assay. Nine laboratories used the toxin AB EIA as a stand-alone assay. The median (range) of examined specimens in one month for the toxin AB EIA, NAAT, and C. difficile culture was 160 (50–2,060), 70 (7–720), and 130 (9–750), respectively. These findings serve as valuable basic data regarding the current status of laboratory diagnosis of CDI in Korea, offering guidance for improved implementation.
Abstract
In May 2015, we conducted a voluntary online survey on laboratory diagnostic assays for Clostridium difficile infection (CDI) across clinical microbiology laboratories in Korea. Responses were obtained from 66 laboratories, including 61 hospitals and five commercial laboratories. Among them, nine laboratories reported having not conducted CDI assays. The toxin AB enzyme immunoassay (toxin AB EIA), nucleic acid amplification test (NAAT), and C. difficile culture, alone or in combination with other assays, were used in 51 (89.5%), 37 (64.9%), and 37 (64.9%) of the remaining 57 laboratories, respectively, and 23 (40.4%) of the laboratories performed all three assays. Only one laboratory used the glutamate dehydrogenase assay. Nine laboratories used the toxin AB EIA as a stand-alone assay. The median (range) of examined specimens in one month for the toxin AB EIA, NAAT, and C. difficile culture was 160 (50–2,060), 70 (7–720), and 130 (9–750), respectively. These findings serve as valuable basic data regarding the current status of laboratory diagnosis of CDI in Korea, offering guidance for improved implementation.
참고문헌 (20)
- Burnham CA, "Diagnosis of Clostridium difficile infection : an ongoing conundrum for clinicians and for clinical laboratories", Clin Microbiol Rev, 26, pp.604~630 (2013)
- Bagdasarian N, "Diagnosis and treatment of Clostridium difficile in adults : a systematic review", JAMA, 313, pp.398~408 (2015)
- Leffler DA, "Clostridium difficile infection", N Engl J Med, 372, pp.1539~1548 (2015)
- Lytvyn L, "Prevention of Clostridium difficile infection : a systematic survey of clinical practice guidelines", Infect Control Hosp Epidemiol, 37, pp.901~908 (2016)
- Kim YS, "Incidence and clinical features of Clostridium difficile infection in Korea : a nationwide study", Epidemiol Infect, 141, pp.189~194 (2013)
- McDonald LC, "Clinical practice guidelines for Clostridium difficile infection in adults and children : 2017 update by the Infectious Diseases Society of America(IDSA)and Society for Healthcare Epidemiology of America(SHEA)", Clin Infect Dis, 66, pp.e1~48 (2018)
- Crobach MJ, "European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection", Clin Microbiol Infect, 22(s4), pp.s63~s81 (2016)
- Surawicz CM, "Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections", Am J Gastroenterol, 108, pp.478~498 (2013)
- van Dorp SM, "Survey of diagnostic and typing capacity for Clostridium difficile infection in Europe, 2011 and 2014", Euro Surveill, pp.21~ (2016)
- Wong KK, "Diagnostic testing methods for Clostridium difficile infection : a statewide survey of Ohio acute care hospitals", Am J Infect Control, 45, pp.306~307 (2017)
- Spigaglia P, "Diagnostic testing for Clostridium difficile in Italian microbiological laboratories", Anaerobe, 37, pp.29~33 (2016)
- Alcalá L, "Impact of clinical awareness and diagnostic tests on the underdiagnosis of Clostridium difficile infection", Eur J Clin Microbiol Infect Dis, 34, pp.1515~1525 (2015)
- Cohen SH, "Clinical practice guidelines for Clostridium difficile infection in adults : 2010 update by the society for healthcare epidemiology of America(SHEA)and the infectious diseases society of America(IDSA)", Infect Control Hosp Epidemiol, 31, pp.431~455 (2010)
- Adler A, "Trends and changes in Clostridium difficile diagnostic policies and their impact on the proportion of positive samples : a national survey", Clin Microbiol Infect, 20, pp.O904~O910 (2014)
- 신보문, "Comparison of ChromID Agar and Clostridium difficile Selective Agar for Effective Isolation of C. difficile from Stool Specimens", Annals of Laboratory Medicine, 34(1), pp.15~19 (2014), 대한진단검사의학회
- 임지숙, "ChromID C. difficile Agar의 Clostridium difficile 배양 평가", Annals of Clinical Microbiology, 15(3), pp.88~91 (2012), 대한임상미생물학회
- 한상봉, "Performance of chromID Clostridium difficile Agar Compared with BBL C. difficile Selective Agar for Detection of C. difficile in Stool Specimens", Annals of Laboratory Medicine, 34(5), pp.376~379 (2014), 대한진단검사의학회
- Fitzpatrick F, "Laboratory diagnosis of Clostridium difficile-associated disease in the Republic of Ireland: a survey of Irish microbiology laboratories", J Hosp Infect, 68, pp.315~321 (2008)
- Könönen E, "Diagnostic trends in Clostridium difficile detection in Finnish microbiology laboratories", Anaerobe, 15, pp.261~265 (2009)
- Shin BM, "Evaluation of the VIDAS glutamate dehydrogenase assay for the detection of Clostridium difficile", Anaerobe, 40, pp.68~72 (2016)